silybin has been researched along with Cancer of Prostate in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (55.17) | 29.6817 |
| 2010's | 24 (41.38) | 24.3611 |
| 2020's | 2 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, QH; Parisis, K; Vue, B; Wang, G; Zhang, Q; Zhang, S; Zhang, X; Zheng, S | 1 |
| Chen, G; Chen, QH; Huang, M; Lee, T; Vue, B; Wang, G; Zhang, Q; Zhang, S; Zhang, X; Zheng, S | 1 |
| Berlin, IG; Jennings, CC; Kenealey, J; Shin, S | 1 |
| Coppo, L; Gonzalez-Menendez, P; Hevia, D; Holmgren, A; Lu, J; Mayo, JC; Rodriguez-Garcia, A; Sainz, RM | 1 |
| Alhado, M; Hernandez, AM; Menge, L; Price, RS; Sherman, B | 1 |
| Agarwal, R; Deep, G; Ting, H | 1 |
| Nambiar, D; Singh, RP | 1 |
| Hadjipavlou, M; Khan, S; Philippou, Y; Rane, A | 1 |
| Agarwal, C; Agarwal, R; Cimic, A; Cramer, SD; Deep, G; Jain, AK; Romero, LM; Sirintrapun, J; Ting, HJ | 1 |
| Babu Bikkina, DJ; Chinde, S; Kulhari, H; Nikhila, N; Pooja, D; Raghavendra, YM; Sreedhar, B; Tiwari, AK | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Jain, AK; Kumar, R | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Nambiar, DK; Singh, RP | 1 |
| Nambiar, DK; Rajamani, P; Singh, RP | 1 |
| Kale, RK; Prajapati, V; Singh, RP | 1 |
| Agarwal, R; Deep, G; Jain, AK; Nambiar, DK; Rajamani, P; Singh, RP | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Jain, AK; Kumar, S; Ting, H | 1 |
| Ahn, SC; Chun, SS; Kim, KY; Kim, SH; Seo, YK; Yu, HS; Yu, SN | 1 |
| Chen, QH; Vue, B | 1 |
| Anestopoulos, I; Chlichlia, K; Franco, R; Kroll, DJ; Panayiotidis, MI; Pappa, A; Sfakianos, AP | 1 |
| Mokhtari, MJ; Motamed, N; Shokrgozar, MA | 1 |
| Agarwal, R; Chittezhath, M; Deep, G; Raina, K; Rajamanickam, S; Singh, RP | 1 |
| Agarwal, R; Deep, G; Kroll, DJ; Oberlies, NH; Raina, K; Singh, RP | 1 |
| Bhatt, RS; Bubley, GJ | 1 |
| Agarwal, R; Raina, K; Sharma, G; Singh, RP | 1 |
| Agarwal, R; Chan, D; Deep, G; Raina, K; Singh, RP | 1 |
| Agarwal, R; Raina, K; Serkova, NJ | 1 |
| Fan, JH; He, DL; Li, L; Wang, XY; Wu, KJ; Zeng, J; Zhang, D; Zhang, LL; Zhu, GD | 1 |
| Baek, WK; Jang, BC; Jung, HJ; Lee, JS; Lee, SR; Park, JW; Suh, MH; Suh, SI | 1 |
| Agarwal, R; Crawford, ED; Flaig, TW; Glodé, M; Gustafson, D; Harrison, G; Li, Y; Lucia, MS; Pollak, M; Su, LJ; Tao, Y; van Bokhoven, A; Wilson, S | 1 |
| Fan, J; He, D; Li, L; Wang, X; Wu, K; Xue, Y; Yang, L; Zeng, J; Zhang, D; Zhu, G | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Gangar, SC | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Gangar, SC; Gu, M; Oberlies, NH; Raina, K; Rajamanickam, S | 1 |
| Bubley, G; Klempner, SJ | 1 |
| Chen, H; King, TD; Li, Y; Lin, C; Lu, W; Reynolds, RC | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Gangar, SC; Jain, AK; Kavitha, CV | 1 |
| Agarwal, C; Agarwal, R; Bhatia, N; Bosland, MC; Condon, MS; Tyagi, A | 1 |
| Agarwal, C; Agarwal, R; Chan, DC; Singh, RP; Tyagi, AK | 1 |
| Agarwal, C; Agarwal, R; Tyagi, A | 1 |
| Agarwal, P; Agarwal, R; Dhanalakshmi, S; Glode, LM | 1 |
| Agarwal, C; Agarwal, R; Dhanalakshmi, S; Sharma, G; Singh, RP | 1 |
| Agarwal, R; Singh, RP | 3 |
| Grzmil, M; Jarry, H; Ringert, RH; Thelen, P; Wuttke, W | 1 |
| Jarry, H; Ringert, RH; Thelen, P; Wuttke, W | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Kroll, DJ; Singh, RP | 1 |
| Agarwal, R; Crighton, F; Flaig, TW; Glodé, LM; Gustafson, DL; Harrison, GS; Pierson, AS; Su, LJ; Zirrolli, JA | 1 |
| Agarwal, R; Flaig, TW; Glodé, LM; Harrison, G; Su, LJ | 1 |
| Gazák, R; Kren, V; Walterová, D | 1 |
| Agarwal, C; Agarwal, R; Kaur, M; Tyagi, A | 1 |
| Comelli, MC; Mengs, U; Prosdocimi, M; Schneider, C | 1 |
| Agarwal, R; Raina, K | 1 |
| Agarwal, R; Blouin, MJ; Deep, G; Pollak, MN; Singh, RP | 1 |
| Agarwal, C; Agarwal, R; Kaur, M; Roy, S; Sclafani, RA; Tecklenburg, M | 1 |
| Agarwal, R; Blouin, MJ; Cohen, P; Deep, G; Glodé, LM; Greenberg, NM; Hwang, D; Majeed, N; Pollak, MN; Raina, K; Singh, RP; Varghese, L | 1 |
| Agarwal, C; Agarwal, R; Sharma, Y; Tyagi, A | 1 |
| Brown, K; Gescher, AJ; Greaves, P; Marsden, DA; Patel, K; Steward, WP; Verschoyle, RD | 1 |
| Agarwal, R; Deep, G; Kroll, DJ; Oberlies, NH | 1 |
12 review(s) available for silybin and Cancer of Prostate
| Article | Year |
|---|---|
Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Chemoprevention; Humans; Male; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin | 2013 |
Advances in prostate cancer chemoprevention: a translational perspective.
Topics: Androgen Antagonists; Animals; Anticarcinogenic Agents; Antioxidants; Azasteroids; Carotenoids; Chemoprevention; Clinical Trials as Topic; Curcumin; Disease Models, Animal; Dutasteride; Finasteride; Flavonoids; Genistein; Humans; Lycopene; Male; Phytochemicals; Polyphenols; Prostate; Prostatic Neoplasms; Risk Factors; Selenium; Silybin; Silymarin; Tea; Vitamin E | 2013 |
Complementary and alternative medicine (CAM) in prostate and bladder cancer.
Topics: Acupuncture; Antineoplastic Agents; Antioxidants; Camellia sinensis; Complementary Therapies; Drugs, Chinese Herbal; Female; Humans; Male; Plant Extracts; Prostatic Neoplasms; Resveratrol; Selenium; Silybin; Silymarin; Stilbenes; Urinary Bladder Neoplasms; Vitamin E; Vitamins | 2013 |
The Potential of Flavonolignans in Prostate Cancer Management.
Topics: Apoptosis; Flavonolignans; Humans; Male; Plant Extracts; Plants, Medicinal; Prostatic Neoplasms; Silybin; Silymarin; Structure-Activity Relationship | 2016 |
The challenge of herbal therapies for prostate cancer.
Topics: Animals; Antineoplastic Agents; Humans; Male; Mice; Phytotherapy; Prostatic Neoplasms; Silybin; Silymarin | 2008 |
Complementary and alternative medicines in prostate cancer: from bench to bedside?
Topics: Antioxidants; Beverages; Complementary Therapies; Curcuma; Humans; Lythraceae; Male; Plant Extracts; Prostatic Neoplasms; Resveratrol; Selenium; Silybin; Silymarin; Stilbenes; Tea; Vitamin E; Vitamins | 2012 |
Prostate cancer prevention by silibinin.
Topics: Animals; Apoptosis; Cell Cycle; Humans; Male; Prostatic Neoplasms; Signal Transduction; Silybin; Silybum marianum; Silymarin | 2004 |
A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
Topics: Animals; Apoptosis; Cell Cycle; Chemoprevention; Humans; Male; Phytotherapy; Prostatic Neoplasms; Signal Transduction; Silybin; Silybum marianum; Silymarin | 2004 |
Prostate cancer chemoprevention by silibinin: bench to bedside.
Topics: Anticarcinogenic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Clinical Trials as Topic; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Male; MAP Kinase Signaling System; NF-kappa B; Prostatic Neoplasms; Receptor, IGF Type 1; Silybin; Silymarin | 2006 |
Silybin and silymarin--new and emerging applications in medicine.
Topics: Angiogenesis Inhibitors; Animal Diseases; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Anticholesteremic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiotonic Agents; Cholagogues and Choleretics; Female; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Receptors, Estrogen; Signal Transduction; Silybin; Silymarin | 2007 |
Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Carcinoma; Cytoprotection; Humans; Liver; Liver Diseases; Male; Oxidative Stress; Prostatic Neoplasms; Protein Kinase Inhibitors; Receptors, Growth Factor; Silybin; Silymarin; Transcription Factors; Tumor Necrosis Factor-alpha | 2007 |
Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytotoxins; Female; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Silybin; Silymarin | 2007 |
2 trial(s) available for silybin and Cancer of Prostate
| Article | Year |
|---|---|
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antioxidants; Combined Modality Therapy; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Middle Aged; Prostate; Prostatectomy; Prostatic Neoplasms; Silybin; Silymarin | 2010 |
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Excipients; Follow-Up Studies; Gastrointestinal Diseases; Glucuronides; Humans; Liver Function Tests; Male; Phosphatidylcholines; Prostatic Neoplasms; Silybin; Silymarin; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet | 2007 |
44 other study(ies) available for silybin and Cancer of Prostate
| Article | Year |
|---|---|
Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; G1 Phase; Humans; Male; Prostate; Prostatic Neoplasms; Silybin; Silymarin | 2016 |
3-O-Alkyl-2,3-dehydrosilibinins: Two synthetic approaches and in vitro effects toward prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Prostatic Neoplasms; Silymarin; Structure-Activity Relationship | 2016 |
Utilizing mixture design response surface methodology to determine effective combinations of plant derived compounds as prostate cancer treatments.
Topics: Androgens; Berberine; Cell Line, Tumor; Docetaxel; Emodin; Humans; Male; Phytochemicals; Prostatic Neoplasms; Silybin | 2023 |
Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells.
Topics: Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Survival; Curcumin; Gene Expression Regulation, Neoplastic; Humans; Male; Melatonin; Prostatic Neoplasms; Reactive Oxygen Species; Resveratrol; Silybin; Silymarin; Stilbenes; Thioredoxins | 2017 |
Silibinin Differentially Decreases the Aggressive Cancer Phenotype in an In Vitro Model of Obesity and Prostate Cancer.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; In Vitro Techniques; Male; Obesity; Prostatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Silybin; Tumor Microenvironment | 2020 |
Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β2.
Topics: Anticarcinogenic Agents; Antioxidants; Cell Differentiation; Cell Line, Tumor; Fibroblasts; Humans; Male; Prostate; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin; Transforming Growth Factor beta2 | 2015 |
Fabrication, characterization and bioevaluation of silibinin loaded chitosan nanoparticles.
Topics: Administration, Oral; Antineoplastic Agents; Cell Line, Tumor; Chemical Phenomena; Chitosan; Drug Carriers; Humans; Male; Nanoparticles; Particle Size; Prostatic Neoplasms; Silybin; Silymarin | 2014 |
Silibinin inhibits fibronectin induced motility, invasiveness and survival in human prostate carcinoma PC3 cells via targeting integrin signaling.
Topics: Animals; Antineoplastic Agents; Antioxidants; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Extracellular Matrix; Fibronectins; Humans; Integrins; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Prostatic Neoplasms; Signal Transduction; Silybin; Silymarin; Xenograft Model Antitumor Assays | 2014 |
Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Humans; Lipid Metabolism; Male; Metribolone; Molecular Targeted Therapy; Phosphorylation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Silybin; Silymarin; Sterol Regulatory Element Binding Protein 1; Sterol Regulatory Element Binding Protein 2; Thiazoles; Transfection | 2014 |
Silibinin attenuates ionizing radiation-induced pro-angiogenic response and EMT in prostate cancer cells.
Topics: Angiogenesis Inducing Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Human Umbilical Vein Endothelial Cells; Humans; Male; Neoplasm Recurrence, Local; Phenotype; Prostatic Neoplasms; Radiation, Ionizing; Silybin; Silymarin; Vascular Endothelial Growth Factor A; Wound Healing | 2015 |
Silibinin combination with arsenic strongly inhibits survival and invasiveness of human prostate carcinoma cells.
Topics: Apoptosis; Arsenic; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Cyclins; Humans; Male; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Oxidative Stress; Prostatic Neoplasms; Reactive Oxygen Species; Silybin; Silymarin; Vimentin | 2015 |
Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling.
Topics: Animals; Apoptosis; Cell Division; Cell Line, Tumor; DNA Damage; DNA Repair; Humans; Male; Mice; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Radiation, Ionizing; Signal Transduction; Silybin; Silymarin; Xenograft Model Antitumor Assays | 2015 |
Beneficial effects of the naturally occurring flavonoid silibinin on the prostate cancer microenvironment: role of monocyte chemotactic protein-1 and immune cell recruitment.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; Cadherins; Cell Line, Tumor; Chemokine CCL2; Culture Media, Conditioned; Fibroblasts; Humans; Male; Mice, Inbred C57BL; NF-kappa B; Prostatic Neoplasms; Silybin; Silymarin; Transcription Factor AP-1; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Silibinin induces mitochondrial NOX4-mediated endoplasmic reticulum stress response and its subsequent apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Humans; Male; Mitochondria; NADPH Oxidase 4; NADPH Oxidases; Prostatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Silybin; Silymarin | 2016 |
A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferases; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase 2; Histones; Humans; Male; Methylation; Neoplasm Proteins; Phosphorylation; Polycomb Repressive Complex 2; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Silybin; Silymarin; Transcription Factors | 2016 |
Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line.
Topics: Adenocarcinoma; Antioxidants; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Humans; Male; Prostatic Neoplasms; Silybin; Silymarin | 2008 |
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Antioxidants; Apoptosis; Biomarkers, Tumor; Blotting, Western; Body Weight; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasm Staging; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: comparison with silymarin and silibinin.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Humans; Male; Mice; Mice, Nude; Microcirculation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Silybin; Silymarin; Time Factors; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2008 |
Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cadherins; Cell Proliferation; Disease Progression; Immunohistochemistry; Male; Matrix Metalloproteinases; Mice; Mice, Transgenic; Neoplasm Metastasis; Neovascularization, Pathologic; Prostatic Neoplasms; Silybin; Silymarin; Vimentin | 2008 |
Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.
Topics: Animals; Antioxidants; Caspase 3; Cell Line, Tumor; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Transplantation; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Silybin; Silymarin; Vascular Endothelial Growth Factor A | 2009 |
Silibinin feeding alters the metabolic profile in TRAMP prostatic tumors: 1H-NMRS-based metabolomics study.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Choline; Citrates; Glucose; Inositol; Lipid Metabolism; Male; Metabolomics; Mice; Mice, Transgenic; Nuclear Magnetic Resonance, Biomolecular; Principal Component Analysis; Prostatic Neoplasms; Silybin; Silymarin | 2009 |
Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression.
Topics: Antioxidants; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Prostatic Neoplasms; Silybin; Silymarin; Vimentin | 2009 |
Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Prostatic Neoplasms; Protein Biosynthesis; Protein Synthesis Inhibitors; Silybin; Silymarin | 2009 |
Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors.
Topics: Antioxidants; Blotting, Western; Cell Adhesion; Cell Line; Cell Movement; Cell Proliferation; Down-Regulation; Epithelial Cells; Fluorescent Antibody Technique; Humans; Keratin-18; Male; Matrix Metalloproteinase 2; Mesoderm; Neoplasm Metastasis; NF-kappa B; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Silybin; Silymarin; Transcription Factors; Up-Regulation; Vimentin | 2010 |
Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells.
Topics: Antioxidants; Cadherins; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; Microscopy, Confocal; Neoplasm Invasiveness; Prostatic Neoplasms; Silybin; Silymarin; src-Family Kinases; Wound Healing | 2011 |
Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.
Topics: Animals; Cell Line; Cell Line, Tumor; Flavonolignans; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin; Xenograft Model Antitumor Assays | 2012 |
Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.
Topics: Antineoplastic Agents; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Female; HEK293 Cells; Humans; Low Density Lipoprotein Receptor-Related Protein-6; Male; Phosphorylation; Prostatic Neoplasms; Signal Transduction; Silybin; Silymarin; Wnt Proteins | 2012 |
Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells.
Topics: Animals; Blotting, Western; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cytokines; Electrophoretic Mobility Shift Assay; Humans; Immunoenzyme Techniques; Macrophages; Male; Mice; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Prostatic Neoplasms; RANK Ligand; Silybin; Silymarin; Transcription Factor AP-1 | 2014 |
Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Topics: Animals; Annexin A5; Apoptosis; Bromodeoxyuridine; Cell Cycle; Cell Division; Coloring Agents; DNA Damage; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Male; Propidium; Prostatic Neoplasms; Rats; Silybin; Silymarin; Trypan Blue; Tumor Cells, Cultured | 2002 |
Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; CDC2 Protein Kinase; Cell Cycle; Cell Division; Cell Separation; Disease Progression; Doxorubicin; Flow Cytometry; G2 Phase; Humans; Male; Mice; Mice, Nude; Mitosis; Neoplasm Transplantation; Prostatic Neoplasms; Silybin; Silymarin; Tumor Cells, Cultured | 2002 |
Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention.
Topics: Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Division; DNA-Binding Proteins; Dose-Response Relationship, Drug; E2F Transcription Factors; E2F1 Transcription Factor; E2F2 Transcription Factor; E2F3 Transcription Factor; G1 Phase; Humans; Immunoblotting; Male; Phosphorylation; Precipitin Tests; Prostatic Neoplasms; Protein Binding; Retinoblastoma Protein; Serine; Silybin; Silymarin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2002 |
Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carboplatin; Caspases; Cell Cycle; Cisplatin; Cytochrome c Group; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunoblotting; Male; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin; Tumor Cells, Cultured | 2003 |
Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspases; Cell Division; Dietary Supplements; Dose-Response Relationship, Drug; Enzyme Activation; Growth Inhibitors; Humans; Insulin-Like Growth Factor Binding Protein 3; Ki-67 Antigen; Male; Mice; Mice, Nude; Neoplasm Transplantation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Silybin; Silymarin; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2003 |
Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Topics: Gene Expression Regulation, Neoplastic; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; RNA, Messenger; Silybin; Silybum marianum; Silymarin; Telomerase; Tumor Cells, Cultured | 2004 |
Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells.
Topics: Cell Line, Tumor; DNA Primers; Down-Regulation; Fruit; Gene Expression Regulation, Neoplastic; Humans; Male; Phytotherapy; Plant Extracts; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Silybin; Silybum marianum; Silymarin; Transcription Factors | 2004 |
Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Topics: Carcinoma; Cell Cycle; Cell Cycle Proteins; Cell Nucleus; Cell Proliferation; Cyclin-Dependent Kinases; Cytoplasm; Flavones; Humans; Male; Phosphorylation; Prostatic Neoplasms; Silybin; Silymarin; Tumor Cells, Cultured | 2006 |
Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Synergism; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Silybin; Silymarin | 2007 |
Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Humans; Janus Kinase 1; Janus Kinase 2; Male; Phosphorylation; Prostatic Neoplasms; Signal Transduction; Silybin; Silymarin; STAT3 Transcription Factor | 2007 |
Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
Topics: Animals; Anticarcinogenic Agents; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Diet; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Insulin-Like Growth Factor Binding Protein 3; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Silybin; Silymarin; Survivin; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2007 |
p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells.
Topics: Antioxidants; Blotting, Western; Bromodeoxyuridine; Cell Differentiation; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; G1 Phase; Humans; Immunoprecipitation; Luciferases; Male; Phosphorylation; Promoter Regions, Genetic; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Silybin; Silybum marianum; Silymarin | 2007 |
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Antioxidants; Disease Models, Animal; Disease Progression; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphorylation; Prostate; Prostatic Neoplasms; Silybin; Silymarin; Species Specificity | 2007 |
Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells.
Topics: Androgens; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Autocrine Communication; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Humans; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; RNA, Messenger; Silybin; Silymarin; Time Factors; Transforming Growth Factor alpha | 2008 |
Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Body Weight; Chromatography, High Pressure Liquid; Drug Evaluation; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Intestinal Neoplasms; Male; Mice; Mice, Inbred C57BL; Phosphatidylcholines; Prostatic Neoplasms; Silybin; Silymarin | 2008 |
Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Blotting, Western; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor Proteins; Cyclin-Dependent Kinases; Cyclins; Drug Screening Assays, Antitumor; Flavonolignans; Flow Cytometry; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Isomerism; Male; Prostatic Neoplasms; Protective Agents; Silybin; Silymarin; Time Factors | 2008 |